Ovagen
A company developing a proprietary process of producing Germ Free chicken eggs and Germ Free birds in commercial quantities for use primarily in the pharmaceutical industry.
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Operator of a veterinary company intended to develop a process of producing germ-free eggs in commercial quantities used primarily in pharmaceutical industries. The company's process facilitates large-scale production of recombinant proteins to GMP standard using a transgenic chicken platform, enabling pharmaceutical companies to have a safe, biosecure, large-scale, flexible, and cost-effective biomanufacturing platform for the production of vaccines and therapeutic proteins.
Keywords: Pharmaceuticals and Biotechnology, Antibody Service, Bacterial Free Egg, Bio Manufacturing Platform, Germ Free, Poultry Husbandry, Production Process, Therapeutic Protein.